Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH 1-44). Its defining structural modification — a trans-3-hexenoyl group on the N-terminus — shields the molecule from rapid cleavage by dipeptidyl peptidase-IV (DPP-IV), extending its biologically active window far beyond that of native GHRH. The downstream mechanism is direct: tesamorelin binds GHRH receptors on pituitary somatotroph cells, amplifying the amplitude and duration of the endogenous pulsatile GH signal. More GH pulses translates to higher integrated GH exposure and, from there, elevated hepatic and peripheral IGF-1 synthesis.
The pivotal human data originates outside the athletics world — specifically in HIV-associated lipodystrophy and NAFLD trials run by Falutz and Stanley and their collaborators — but the mechanistic read-through to recovery physiology is direct and has not been lost on investigators. Falutz et al. (2007, NEJM) ran a 412-subject, double-blind, placebo-controlled trial of tesamorelin 2 mg/day SC over 26 weeks and recorded a ~50% rise in IGF-1 versus placebo, alongside a 15–18% reduction in visceral adipose tissue. That IGF-1 number is the figure sports-science investigators cite first, because IGF-1 is the primary signalling molecule through which GH exerts its anabolic effects on skeletal muscle, connective tissue, satellite cells and bone matrix.
Nothing in this post constitutes medical advice or a therapeutic dosing recommendation. All references to investigator use of tesamorelin are in the context of legitimate research applications. For researchers in the UAE who need verified, cold-chain-dispatched supply, REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates — tesamorelin 5 mg and 10 mg vials, in stock now.
The connection between tesamorelin and athletic recovery research runs directly through sleep physiology. The majority of endogenous GH secretion — approximately 70–80% of the total nocturnal pulse in healthy adults — occurs during slow-wave sleep (SWS), specifically NREM stages 3 and 4. This is not incidental: the hypothalamic GHRH surge that triggers the first and largest nocturnal GH pulse aligns tightly with sleep-onset SWS entry, typically 60–90 minutes after lying down.
Age, caloric restriction, elevated cortisol and accumulated sleep debt all attenuate this signal. The result — a blunted nocturnal GH axis and the consequent IGF-1 deficit — is one mechanism proposed to explain the slowed recovery kinetics observed in over-trained athletes, veterans with high training loads, and individuals under significant life stress. Investigators asking whether GHRH-class peptides can restore or amplify the SWS-gated GH signal are working with this physiological rationale.
Neuroendocrinological research separate from the Falutz and Stanley lipodystrophy literature has examined GHRH-class peptides specifically for their interaction with sleep architecture. Studies by Born et al. and Kerkhofs et al. in sleep-laboratory conditions showed that exogenous GHRH administration increased SWS duration and GH pulse amplitude — an effect attributed to direct hypothalamic GHRH receptor activity influencing sleep-stage regulation. Tesamorelin, as a DPP-IV-stabilized GHRH analog with documented GH-pulsatility amplification, is mechanistically positioned to engage the same receptors. Investigators working in sleep-biology or athletic-recovery contexts will naturally assess whether the molecule's documented IGF-1-raising effect in the Falutz cohorts translates to relevant changes in sleep-stage GH kinetics.
IGF-1 is not merely a biomarker of GH activity — it is the primary effector molecule for GH's anabolic actions in peripheral tissue. The relevant actions for athletic recovery include:
A ~50% IGF-1 elevation — the figure from Falutz 2007 — represents a substantial endogenous upregulation of all of these pathways simultaneously. The mechanism does not require exogenous IGF-1; it simply augments the GHRH → GH → IGF-1 axis at its origin.
The four published trials are the complete legitimate citation set for tesamorelin. Investigators should not use references beyond these — the literature outside this set is either in vitro, animal-only, or insufficiently powered for human mechanistic conclusions about tesamorelin specifically.
| Study | Design | n | Key Findings |
|---|---|---|---|
| Falutz et al. 2007 (NEJM) | RCT, 26 weeks, tesamorelin 2 mg/day SC vs placebo | 412 | VAT −15–18% vs placebo; IGF-1 +~50% vs placebo; well-tolerated |
| Falutz et al. 2010 (JCEM) | 26-week open-label extension of the 2007 trial | 273 | VAT reduction maintained or extended; IGF-1 elevation sustained through 52 weeks total |
| Stanley et al. 2014 (JAMA) | RCT, 12 months, tesamorelin 2 mg/day SC vs placebo (HIV NAFLD) | 50 | Liver fat −32% vs placebo; IGF-1 elevated; visceral fat reduced |
| Stanley et al. 2019 (Lancet HIV) | RCT, 12 months, tesamorelin 2 mg/day SC vs placebo (HIV NAFLD multicentre) | 61 | Liver fat reduction confirmed; metabolic markers improved; sustained IGF-1 response documented |
Every published trial used 2 mg/day SC as the primary research dose. The IGF-1 elevation was consistent across populations and trial durations. Investigators note that the Falutz 2010 extension data confirms the effect is not transient — IGF-1 remained elevated through the full 52-week period without tachyphylaxis signals, which is mechanistically expected given that tesamorelin acts on endogenous GH production rather than replacing it.
For investigators designing protocols referencing the published literature, the anchoring dose is 2 mg/day SC, as used in Falutz 2007, Stanley 2014 and Stanley 2019. Some dose-finding and titration contexts in the investigator literature reference 1 mg/day. REVIVE LAB UAE stocks only tesamorelin 5 mg vials and tesamorelin 10 mg vials — both sizes support these research-context dose levels with straightforward reconstitution. No 1 mg or 2 mg vials are stocked, as these do not represent supply-grade presentations.
| Vial Size | BAC Water Added | Concentration | Volume for 1 mg (research ref) | Volume for 2 mg (research ref) |
|---|---|---|---|---|
| Tesamorelin 5 mg | 2 mL | 2.5 mg / mL | 0.4 mL | 0.8 mL |
| Tesamorelin 5 mg | 1 mL | 5 mg / mL | 0.2 mL | 0.4 mL |
| Tesamorelin 10 mg | 2 mL | 5 mg / mL | 0.2 mL | 0.4 mL |
| Tesamorelin 10 mg | 4 mL | 2.5 mg / mL | 0.4 mL | 0.8 mL |
Reconstituted vials require 2-8°C storage and are stable for approximately 14 days. Lyophilized (un-reconstituted) vials from REVIVE LAB UAE are stable at 2-8°C for the duration marked on the batch COA. Always reconstitute by injecting bacteriostatic water slowly down the inside wall of the vial — not directly onto the lyophilized cake. Swirl gently; do not vortex.
The ~50% IGF-1 rise in Falutz 2007 deserves unpacking. The Falutz cohort was a lipodystrophy population — not healthy athletes — so IGF-1 baseline values were lower than in trained individuals. Investigators studying athletic recovery populations may therefore be working with a different starting IGF-1 level and should not assume an identical percentage change. What the Falutz data establishes is the mechanism: tesamorelin reliably recruits the endogenous GH → IGF-1 axis at scale over multi-month research windows, with an acceptable safety profile in human subjects and no evidence of desensitization over the observed study periods.
The Stanley 2014 JAMA paper adds another mechanistic dimension relevant to investigators focused on metabolic recovery. The 32% liver fat reduction vs placebo is a metabolic phenotype shift — hepatic lipid clearance improved in parallel with IGF-1 elevation. For athletic-recovery researchers, this raises the question of whether tesamorelin's metabolic effects (VAT reduction, liver fat reduction, IGF-1 elevation) converge on a composite recovery-state phenotype that goes beyond purely anabolic endpoints. This is an open investigational question; the published literature addresses lipodystrophy and NAFLD populations specifically.
Investigators who want to buy tesamorelin UAE for research and need verified purity documentation will find that REVIVE LAB UAE provides third-party HPLC results and lot-specific COAs as standard — the same documentation standard the Falutz and Stanley investigational teams operated under, adapted for the UAE research supply chain.
If tesamorelin's core mechanism is amplification of the endogenous GHRH → GH pulse, and the dominant nocturnal GH pulse occurs in the SWS window 60–90 minutes after sleep onset, then the timing of administration becomes a variable of active investigational interest. The Falutz 2007 protocol used once-daily SC administration without specifying a tight sleep-anchored window. Investigators asking whether pre-sleep administration produces a meaningfully different IGF-1 or GH AUC profile compared to morning administration are operating on a legitimate mechanistic hypothesis — one that has not been specifically addressed in the published tesamorelin literature to date.
This gap is one reason REVIVE LAB UAE continues to see demand from researchers across Dubai Sports City, Al Quoz, DIFC and Abu Dhabi's athlete-services sector who are constructing tesamorelin protocols around sleep-timing hypotheses. The molecule is research-grade, the mechanism is well-characterised, and the UAE's research community has access to consistent, verified supply through a local source rather than offshore shipping with cold-chain uncertainty.
REVIVE LAB UAE is a Dubai-based peptides UAE research supplier — not a reseller, not an offshore drop-shipper, and not a label on someone else's vial. Every tesamorelin batch is HPLC-tested at ≥99% purity with lot-specific COA available on request, shipped in validated cold-chain insulation that maintains 2-8°C through any UAE summer transit. Tesamorelin 5 mg and 10 mg are in stock, dispatched same-day on weekdays with plain, unbranded outer packaging and cash on delivery available UAE-wide.
| Emirate / City | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm, Jumeirah, Sports City) | Same-day, 4–8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem, Khalidiyah) | Next-day, 18–24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8–18 hours | Yes | Yes |
| Ajman | Next-day, 18–24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18–24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18–24 hours | Yes | Yes |
| Al Ain | Next-day, 24 hours | Yes | Yes |
A researcher in Dubai ordering before the daily cut-off receives cold-pack tesamorelin vials the same day — whether in Dubai Marina, Business Bay, JVC, DIFC, Palm Jumeirah, Jumeirah, Downtown or Emirates Hills. Tesamorelin same day Dubai is the baseline, not a premium tier. For the broader peptides UAE research stack — Retatrutide, GHK-Cu, BPC-157, TB-500, Semax, NAD+, MOTS-c — see the full REVIVE LAB UAE catalogue.
Falutz et al. (2007, NEJM) demonstrated a ~50% rise in IGF-1 in subjects receiving tesamorelin 2 mg/day SC over 26 weeks versus placebo — the largest and most rigorous human dataset for this molecule. IGF-1 is the primary effector of GH's anabolic actions on skeletal muscle, satellite cells, connective tissue and bone. Investigators focused on athletic recovery hypothesize that amplifying the endogenous GHRH → GH → IGF-1 axis during the slow-wave sleep window — when 70–80% of nocturnal GH secretion occurs — could optimize repair kinetics. This remains an active investigational area; the Falutz and Stanley clinical trials were conducted in lipodystrophy and NAFLD populations, not athletic cohorts. All use references here are to research contexts only.
REVIVE LAB UAE stocks tesamorelin 5 mg vials and tesamorelin 10 mg vials — no other strengths are carried. The Falutz 2007 and 2010 trials and both Stanley trials used 2 mg/day SC as the primary research-context dose. Some investigator protocols reference 1 mg/day for dose-finding or titration contexts. Both dose levels are achievable with standard reconstitution using bacteriostatic water from REVIVE LAB UAE 5 mg or 10 mg vials. HPLC purity ≥99% and lot-specific COAs are included with every batch.
Yes. REVIVE LAB UAE offers tesamorelin same day Dubai delivery for weekday orders placed before the daily cut-off, and tesamorelin 24h delivery to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, UAQ and Al Ain. Cash on delivery is available across all 7 emirates. All shipments are cold-chain dispatched in plain, unbranded outer packaging from REVIVE LAB UAE's Dubai facility. Tesamorelin is supplied for research use only.